Naruse Hiroyuki, Ishii Junnichi, Takahashi Hiroshi, Kitagawa Fumihiko, Sakaguchi Eirin, Nishimura Hideto, Kawai Hideki, Muramatsu Takashi, Harada Masahide, Yamada Akira, Fujiwara Wakaya, Hayashi Mutsuharu, Motoyama Sadako, Sarai Masayoshi, Watanabe Eiichi, Ito Hiroyasu, Ozaki Yukio, Izawa Hideo
Faculty of Medical Technology, School of Health Sciences, Fujita Health University, Toyoake 470-1192, Japan.
Department of Joint Research Laboratory of Clinical Medicine, Bantane Hospital, Nagoya 454-8509, Japan.
J Clin Med. 2021 Aug 13;10(16):3564. doi: 10.3390/jcm10163564.
The prognostic role of D-dimer in different types of heart failure (HF) is poorly understood. We investigated the prognostic value of D-dimer on admission, both independently and in combination with the Get With The Guidelines-Heart Failure (GWTG-HF) risk score and N-terminal pro-B-type natriuretic peptide (NT-proBNP), in patients with preserved left ventricular ejection fraction (LVEF) and acute decompensated HF (HFpEF) or reduced LVEF (HFrEF). Baseline D-dimer levels were measured on admission in 1670 patients (mean age: 75 years) who were hospitalized for worsening HF. Of those patients, 586 (35%) were categorized as HFpEF (LVEF ≥ 50%) and 1084 as HFrEF (LVEF < 50%). During the 12-month follow-up period after admission, 360 patients died. Elevated levels (at least the highest tertile value) of D-dimer, GWTG-HF risk score, and NT-proBNP were all independently associated with mortality in all HFpEF and HFrEF patients (all < 0.05). Adding D-dimer to a baseline model with a GWTG-HF risk score and NT-proBNP improved the net reclassification and integrated discrimination improvement for mortality greater than the baseline model alone in all populations (all < 0.001). The number of elevations in D-dimer, GWTG-HF risk score, and NT-proBNP were independently associated with a higher risk of mortality in all study populations (HFpEF and HFrEF patients; all < 0.001). The combination of D-dimer, which is independently predictive of mortality, with the GWTG-HF risk score and NT-proBNP could improve early prediction of 12-month mortality in patients with acute decompensated HF, regardless of the HF phenotype.
D - 二聚体在不同类型心力衰竭(HF)中的预后作用尚不清楚。我们研究了入院时D - 二聚体的预后价值,其单独以及与“遵循心力衰竭治疗指南”(GWTG - HF)风险评分和N末端B型利钠肽原(NT - proBNP)联合使用时,对左心室射血分数(LVEF)保留的急性失代偿性HF(HFpEF)或LVEF降低(HFrEF)患者的预后价值。对1670例因HF加重而住院的患者(平均年龄:75岁)入院时测量基线D - 二聚体水平。在这些患者中,586例(35%)被归类为HFpEF(LVEF≥50%),1084例为HFrEF(LVEF<50%)。在入院后的12个月随访期内,360例患者死亡。D - 二聚体、GWTG - HF风险评分和NT - proBNP水平升高(至少为最高三分位数)均与所有HFpEF和HFrEF患者的死亡率独立相关(均P<0.05)。在包含GWTG - HF风险评分和NT - proBNP的基线模型中加入D - 二聚体,在所有人群中,对死亡率的净重新分类和综合判别改善均优于单独的基线模型(均P<0.001)。D - 二聚体、GWTG - HF风险评分和NT - proBNP升高的次数与所有研究人群(HFpEF和HFrEF患者)的较高死亡风险独立相关(均P<0.001)。无论HF表型如何,独立预测死亡率的D - 二聚体与GWTG - HF风险评分和NT - proBNP联合使用可改善急性失代偿性HF患者12个月死亡率的早期预测。